Physiomics PLC Appointment of Independent Non-Executive Director (3065G)
March 29 2022 - 2:01AM
UK Regulatory
TIDMPYC
RNS Number : 3065G
Physiomics PLC
29 March 2022
29 March 2022
Physiomics plc
("Physiomics") or ("the Company")
Physiomics appoints new Independent Non-Executive Director
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, is pleased to announce that Dr Tim
Corn will join the Company's board as an Independent Non-Executive
Director from 1 April 2022.
Dr Tim Corn qualified in medicine at King's College Hospital
and, after becoming honorary Consultant and Senior Lecturer, joined
the pharmaceutical industry in 1983. He has held senior positions
in both big and small pharma as well as at the MHRA and became
Chief Medical Officer ("CMO") of several small but highly
successful venture-backed companies, such as EUSA Pharma and Zeneus
Pharma. He has played a key role in more than twenty regulatory
approvals in the USA and Europe, is the author of more than forty
scientific publications, and was elected Fellow of both the Faculty
of Pharmaceutical Medicine and the Royal College of Psychiatrists.
Tim previously served as Chairman and Non-Executive Director on the
Board of Reneuron plc (AIM: RENE), and currently serves as a
Trustee of Nerve Tumours UK, and as CMO of Nodenza Inc.
Dr Jim Millen, CEO, commented : "My colleagues and I are
delighted to have been able to attract someone of Tim's calibre and
experience to our board of directors. Tim is perfectly positioned
to advise us on issues relating to our core consulting business and
has already provided valuable input into the discussion of
strategic initiatives through his participation in our advisory
board last year. I'd like to personally welcome Tim to the Company
and look forward to working with him going forwards."
Further information on Tim Corn's appointment :
The following details in relation to the appointment of Dr
Timothy ("Tim") Corn are disclosed in accordance with AIM Rule 17
and Schedule 2(g) of the AIM Rules:
Timothy Henry Corn (aged 70 ) has held the following
directorships in the past five years.
Past Directorships / Partnerships
Current Directorships / Partnerships (last five years)
Reneuron Group plc Neurocentrx Pharma Limited
----------------------------------
The Neurofibromatosis Association Circassia Group PLC
----------------------------------
Zenios Bioscience LLP HERA
----------------------------------
Aesclepius Consulting Ltd
----------------------------------
Carter Communications Ltd
----------------------------------
Tots with Tumours Ltd
----------------------------------
Kids with Tumours Ltd
----------------------------------
Children with Tumours Ltd
----------------------------------
There is no further information to be disclosed in relation to
Tim Corn's appointment pursuant to AIM Rule 17 or Schedule Two,
paragraph (g) (i)-(viii) of the AIM Rules for Companies.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFLFEDVRITFIF
(END) Dow Jones Newswires
March 29, 2022 02:01 ET (06:01 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024